Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition
BCL-XL and BCL-2 are important targets for cancer treatment. BCL-XL specific proteolysis-
targeting chimeras (PROTACs) have been developed to circumvent the on-target platelet …
targeting chimeras (PROTACs) have been developed to circumvent the on-target platelet …
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity
Anti-apoptotic protein BCL-X L plays a key role in tumorigenesis and cancer chemotherapy
resistance, rendering it an attractive target for cancer treatment. However, BCL-X L inhibitors …
resistance, rendering it an attractive target for cancer treatment. However, BCL-X L inhibitors …
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines
Abstract Targeting BCL-X L via PROTACs is a promising strategy in reducing BCL-X L
inhibition associated platelet toxicity. Recently, we reported potent BCL-X L PROTAC …
inhibition associated platelet toxicity. Recently, we reported potent BCL-X L PROTAC …
Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL
BCL-XL, an anti-apoptotic BCL-2 family protein, plays a key role in cancer cell survival.
However, the potential of BCL-XL as an anti-cancer target has been hampered by the on …
However, the potential of BCL-XL as an anti-cancer target has been hampered by the on …
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
B-cell lymphoma extra large (BCL-XL) is a well-validated cancer target. However, the on-
target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors, such as …
target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors, such as …
[HTML][HTML] PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
Abstract BCL-X L is an anti-apoptotic protein that plays an important role in tumorigenesis,
metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-X L …
metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-X L …
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity
Abstract PROteolysis-TArgeting Chimeras (PROTACs) have emerged as an innovative drug
development platform. However, most PROTACs have been generated empirically because …
development platform. However, most PROTACs have been generated empirically because …
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL
Overexpression of BCL-xL and BCL-2 play key roles in tumorigenesis and cancer drug
resistance. Advances in PROTAC technology facilitated recent development of the first BCL …
resistance. Advances in PROTAC technology facilitated recent development of the first BCL …
Structural insights into PROTAC-mediated degradation of Bcl-xL
C Chung, H Dai, E Fernandez, CP Tinworth… - ACS Chemical …, 2020 - ACS Publications
The Bcl-2 family of proteins, such as Bcl-xL and Bcl-2, play key roles in cancer cell survival.
Structural studies of Bcl-xL formed the foundation for the development of the first Bcl-2 family …
Structural studies of Bcl-xL formed the foundation for the development of the first Bcl-2 family …
[HTML][HTML] Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells
Abstract BCL-X L and BCL-2 are key anti-apoptotic proteins and validated cancer targets.
753B is a novel BCL-X L/BCL-2 proteolysis targeting chimera (PROTAC) that targets both …
753B is a novel BCL-X L/BCL-2 proteolysis targeting chimera (PROTAC) that targets both …